In risk assessment phase 1 without biases‐pairing (Figure 1S), substantially increased incidence risks of pancreatitis, gastric ulcer, acute nephritis, and leukemia were observed in both short‐term and/or long‐term usage of GLP‐1 RAs when compared with insulin subcutaneous injection group. The gene discussed is INS; the disease is pancreatitis.